Navigation Links
Eltrombopag studied in Idiopathic Thrombocytopenic Purpura
Date:11/28/2007

NEW YORK (Nov. 29, 2007) -- There are estimated to be between 50,000 -- 100,000 individuals in the U.S. diagnosed with chronic Immune Thrombocytopenic Purpura (ITP), an autoimmune disease that dramatically reduces the number of platelets in their blood -- causing bruises, nosebleeds and, sometimes, life-threatening brain hemorrhages. Now, the results of an international multicenter clinical research study led by NewYork-Presbyterian Hospital/Weill Cornell Medical Center demonstrate that an investigational oral platelet growth factor called eltrombopag successfully increased platelet counts and decreased bleeding in patients with the condition.

Published in today's New England Journal of Medicine and representing the largest ever clinical trial of its kind for ITP patients, the Phase 2 study found that eltrombopag doses of 50 and 75 mg daily elevated platelet counts to a safe level (= 50,000 per cubic millimeter) in more than 75 percent of chronic ITP patients within two weeks -- compared to 11 percent of patients receiving placebo. As long as the therapy was administered, platelet counts continued to rise or remain increased, and bleeding symptoms decreased. Incidence and severity of adverse effects was similar in the placebo and eltrombopag treated groups.

"These findings represent an important step in the development of a new treatment option for those living with chronic ITP. The fact that eltrombopag elevated platelet counts in this study within one week could be very useful to chronic ITP patients in need of short-term treatment," says the study's principal investigator, Dr. James Bussel, director of the platelet research and treatment program at the Phyllis and David Komansky Center for Children's Health at NewYork-Presbyterian Hospital/Weill Cornell Medical Center and professor of pediatrics in obstetrics and gynecology and in medicine at Weill Cornell Medical College.

The study represents the second major clinical study of a platelet growth factor for ITP. In October 2006, Dr. Bussel was the lead author of publication reporting the results of a Phase I, II study of AMG 531, also in the New England Journal of Medicine.

Current and future studies will evaluate the safety and efficacy of eltrombopag as a long-term treatment for ITP, and its efficacy and safety in populations like the four million Americans with hepatitis C or patients receiving myelosuppressive chemotherapy.


'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Related medicine news :

1. New treatment option studied for bladder cancer
2. Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... BC (PRWEB) , ... July 26, 2017 , ... ... (the “Company” or “Isodiol”) a global cannabis innovator, specializing in the development of ... the period from April 1, 2017 to June 30, 2017. Iso International LLC ...
(Date:7/26/2017)... ... 26, 2017 , ... The number of adults 65 years or older is ... improve asthma control in the population are not well described. In a study published ... official journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), researchers identified ...
(Date:7/25/2017)... ... July 25, 2017 , ... Creative Pharmacist and ... provide the Pharmacist eCare Plan to Computer-Rx pharmacies through the STRAND ... ability to develop the Pharmacist eCare Plan, a shared document detailing a patient’s ...
(Date:7/25/2017)... ... July 25, 2017 , ... Nautilus Hyosung ... States, today announced its partnership with financial technology company, Automated Transaction Delivery (ATD), ... the solution lies within Hyosung’s superior ATMs, assisted self-service devices and associated software. ...
(Date:7/25/2017)... ... 2017 , ... SignatureCare Emergency Center – South Austin is treating both adult ... day. , The Emergency Room opened early March, making it the ... now and things are running smoothly,” said Aaron Braun, SignatureCare Emergency Center’s Chief Medical ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... 13, 2017  Centurion Medical Products, a leader in medical product ... fecal impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part ... alleviate patient pain while preventing unneeded emergency department admission due to ...
(Date:7/12/2017)... -- Eli Lilly and Company (NYSE: LLY ) has ... pending patent litigation in the U.S. District Court for the ... Cialis ® (tadalafil) unit dose patent. This patent was ... of the agreement, Cialis exclusivity is now expected to end ... unit dose patent for Cialis is valid and infringed by ...
(Date:7/11/2017)... 11, 2017  Sysmex America, Inc., a leading ... equipment as well as middleware information systems technology, ... make quality assurance easier and more risk free ... known for the innovation that it delivers to ... quality assurance processes to a new level with ...
Breaking Medicine Technology: